Phillip W. Berman - Publications

Affiliations: 
Biomolecular Engineering University of California, Santa Cruz, Santa Cruz, CA, United States 
Area:
Drug development, vaccines, AIDS, monoclonal antibody therapeutics, immunology, molecular cell/biology, recombinant protein production
Website:
http://www.soe.ucsc.edu/people/pwb

86 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Li SW, Wright M, Healey JF, Hutchinson JM, O'Rourke S, Mesa KA, Lollar P, Berman PW. Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens. Plos One. 15: e0233866. PMID 32470085 DOI: 10.1371/Journal.Pone.0233866  0.515
2019 Hutchinson JM, Mesa KA, Alexander DL, Yu B, O'Rourke SM, Limoli KL, Wrin T, Deeks SG, Berman PW. Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. Frontiers in Immunology. 10: 1021. PMID 31156622 DOI: 10.3389/Fimmu.2019.01021  0.498
2019 Li S, Yu B, Byrne G, Wright M, O'Rourke S, Mesa K, Berman PW. Identification and CRISPR/Cas9 Knockout of the Endogenous C1s Protease in CHO Cells Eliminates Aberrant Proteolysis of Recombinantly Expressed Proteins. Biotechnology and Bioengineering. PMID 31087560 DOI: 10.1002/Bit.27016  0.52
2019 Mesa KA, Yu B, Wrin T, Petropoulos CJ, Pogson GH, Alexander DL, Perez G, O'Rourke SM, Sinangil F, Robinson J, Conant MA, Berman PW. Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens. Plos One. 14: e0213409. PMID 30969970 DOI: 10.1371/Journal.Pone.0213409  0.537
2018 O'Rourke SM, Yu B, Morales JF, Didinger CM, Alexander DL, Vollmers C, Berman PW. Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins. Journal of Immunological Methods. PMID 30502324 DOI: 10.1016/J.Jim.2018.11.015  0.656
2018 Doran RC, Yu B, Wright M, O'Rourke SM, Yin L, Richardson JM, Byrne G, Mesa KA, Berman PW. Development of a Stable MGAT1 CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies. Frontiers in Immunology. 9: 2313. PMID 30344523 DOI: 10.3389/Fimmu.2018.02313  0.577
2018 Byrne G, O'Rourke SM, Alexander DL, Yu B, Doran RC, Wright M, Chen Q, Azadi P, Berman PW. CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation. Plos Biology. 16: e2005817. PMID 30157178 DOI: 10.1371/Journal.Pbio.2005817  0.517
2018 O'Rourke SM, Byrne G, Tatsuno G, Wright M, Yu B, Mesa KA, Doran RC, Alexander D, Berman PW. Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production. Plos One. 13: e0197656. PMID 30071025 DOI: 10.1371/Journal.Pone.0197656  0.454
2018 Doran RC, Tatsuno GP, O'Rourke SM, Yu B, Alexander DL, Mesa KA, Berman PW. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies. Plos One. 13: e0196370. PMID 29689099 DOI: 10.1371/Journal.Pone.0196370  0.55
2018 Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, et al. HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology. PMID 29386288 DOI: 10.1128/Jvi.01843-17  0.574
2018 Frey BF, Jiang J, Sui Y, Boyd LF, Yu B, Tatsuno G, Billeskov R, Solaymani-Mohammadi S, Berman PW, Margulies DH, Berzofsky JA. Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity. Journal of Immunology (Baltimore, Md. : 1950). PMID 29374075 DOI: 10.4049/Jimmunol.1701523  0.479
2017 Wang K, Tomaras GD, Jegaskanda S, Moody MA, Liao HX, Goodman K, Berman PW, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Haynes BF, Cohen JI. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate ADCC, and Protect Mice from Ocular Challenge with HSV-1. Journal of Virology. PMID 28701403 DOI: 10.1128/Jvi.00411-17  0.568
2017 Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, et al. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. Plos One. 12: e0180720. PMID 28678869 DOI: 10.1371/Journal.Pone.0180720  0.526
2017 Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, ... ... Berman PW, et al. Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. Plos One. 12: e0176428. PMID 28493891 DOI: 10.1371/Journal.Pone.0176428  0.551
2017 Aiyegbo MS, Shmelkov E, Dominguez L, Goger M, Battacharya S, deCamp AC, Gilbert PB, Berman PW, Cardozo T. Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure. Plos One. 12: e0170530. PMID 28107435 DOI: 10.1371/Journal.Pone.0170530  0.514
2016 Morales JF, Yu B, Perez G, Mesa KA, Alexander DL, Berman PW. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody. Molecular Immunology. 77: 14-25. PMID 27449907 DOI: 10.1016/J.Molimm.2016.07.003  0.701
2015 O'Rourke SM, Sutthent R, Phung P, Mesa KA, Frigon NL, To B, Horthongkham N, Limoli K, Wrin T, Berman PW. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses. Plos One. 10: e0119608. PMID 25793890 DOI: 10.1371/Journal.Pone.0119608  0.581
2014 Doran RC, Morales JF, To B, Morin TJ, Theolis R, O'Rourke SM, Yu B, Mesa KA, Berman PW. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. Molecular Immunology. 62: 219-26. PMID 25016576 DOI: 10.1016/J.Molimm.2014.06.025  0.713
2014 Morales JF, Morin TJ, Yu B, Tatsuno GP, O'Rourke SM, Theolis R, Mesa KA, Berman PW. HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1. The Journal of Biological Chemistry. 289: 20526-42. PMID 24872420 DOI: 10.1074/Jbc.M114.554089  0.696
2014 Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine. 6: 228ra39. PMID 24648342 DOI: 10.1126/Scitranslmed.3007730  0.551
2013 Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. Plos One. 8: e75665. PMID 24086607 DOI: 10.1371/Journal.Pone.0075665  0.579
2013 Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. Plos One. 8: e53629. PMID 23349725 DOI: 10.1371/Journal.Pone.0053629  0.575
2013 Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL, Kozink DM, Stewart S, Anasti K, Jaeger FH, ... ... Berman PW, et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. Journal of Virology. 87: 1554-68. PMID 23175357 DOI: 10.1128/Jvi.00718-12  0.403
2012 O'Rourke SM, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, To B, Sinangil F, Limoli K, Wrin T, Berman PW. Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. Journal of Virology. 86: 12105-14. PMID 22933284 DOI: 10.1128/Jvi.01352-12  0.542
2012 Yu B, Morales JF, O'Rourke SM, Tatsuno GP, Berman PW. Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. Plos One. 7: e43903. PMID 22928048 DOI: 10.1371/Journal.Pone.0043903  0.682
2012 Nakamura GR, Fonseca DP, O'Rourke SM, Vollrath AL, Berman PW. Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding. Plos One. 7: e39045. PMID 22720026 DOI: 10.1371/Journal.Pone.0039045  0.557
2012 Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, ... ... Berman PW, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. The Journal of Infectious Diseases. 206: 431-41. PMID 22634875 DOI: 10.1093/Infdis/Jis367  0.534
2012 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, ... ... Berman PW, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England Journal of Medicine. 366: 1275-86. PMID 22475592 DOI: 10.1056/Nejmoa1113425  0.514
2012 O'Rourke S, Sutthent R, Limoli K, Phung P, Tatsuno G, To B, Mesa K, Frigon N, Higgins K, Wrin T, Berman P. Mapping epitopes on CRF01_AE viruses recognized by broadly neutralizing antibodies in sera from elite neutralizers from North America and Thailand Retrovirology. 9: 90. DOI: 10.1186/1742-4690-9-S2-P90  0.502
2012 Yu B, O’Rourke S, Morales J, Tatsuno G, Mesa K, Berman P. Antigen processing sites in gp120 are conserved across HIV virus clades. Retrovirology. 9: 297. DOI: 10.1186/1742-4690-9-S2-P297  0.66
2011 Pérez-Losada M, Jobes DV, Sinangil F, Crandall KA, Arenas M, Posada D, Berman PW. Phylodynamics of HIV-1 from a phase III AIDS vaccine trial in Bangkok, Thailand. Plos One. 6: e16902. PMID 21423744 DOI: 10.1371/Journal.Pone.0016902  0.476
2010 Smith DH, Winters-Digiacinto P, Mitiku M, O'Rourke S, Sinangil F, Wrin T, Montefiori DC, Berman PW. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. Plos One. 5: e12076. PMID 20711452 DOI: 10.1371/Journal.Pone.0012076  0.62
2010 O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, Sinangil F, Berman PW. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. Journal of Virology. 84: 11200-9. PMID 20702624 DOI: 10.1128/Jvi.00790-10  0.535
2010 Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. The Journal of Infectious Diseases. 202: 595-605. PMID 20608874 DOI: 10.1086/654816  0.563
2010 Yu B, Fonseca DP, O'Rourke SM, Berman PW. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. Journal of Virology. 84: 1513-26. PMID 19939935 DOI: 10.1128/Jvi.01765-09  0.576
2010 Pérez-Losada M, Jobes DV, Sinangil F, Crandall KA, Posada D, Berman PW. Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America. Molecular Biology and Evolution. 27: 417-25. PMID 19864468 DOI: 10.1093/Molbev/Msp254  0.508
2009 Pérez-Losada M, Posada D, Arenas M, Jobes DV, Sinangil F, Berman PW, Crandall KA. Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. Retrovirology. 6: 67. PMID 19604405 DOI: 10.1186/1742-4690-6-67  0.456
2009 O'Rourke SM, Schweighardt B, Scott WG, Wrin T, Fonseca DP, Sinangil F, Berman PW. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. Journal of Virology. 83: 7728-38. PMID 19474108 DOI: 10.1128/Jvi.00688-09  0.531
2009 Berman P, O'Rourke SM, Schweighardt B, Sinangil F, Wrin T. P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies Retrovirology. 6: P396. DOI: 10.1186/1742-4690-6-S3-P396  0.539
2006 Jobes DV, Daoust M, Nguyen V, Padua A, Michele S, Lock MD, Chen A, Sinangil F, Berman PW. High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a Phase 3 vaccine efficacy trial. Aids Research and Human Retroviruses. 22: 1014-21. PMID 17067272 DOI: 10.1089/aid.2006.22.1014  0.448
2006 Jobes DV, Daoust M, Nguyen VT, Padua A, Sinangil F, Pérez-Losada M, Crandall KA, Oliphant T, Posada D, Rambaut A, Fuchs J, Berman PW. Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial. Aids Research and Human Retroviruses. 22: 968-78. PMID 17067266 DOI: 10.1089/Aid.2006.22.968  0.465
2005 Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. The Journal of Infectious Diseases. 192: 974-83. PMID 16107949 DOI: 10.1086/432734  0.397
2005 Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. The Journal of Infectious Diseases. 191: 666-77. PMID 15688279 DOI: 10.1086/428405  0.477
2004 Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, Hirunras K, Kitayaporn D, Kaewkangwal J, Migasena S, Sheppard HW, Li E, Chernow M, Peterson ML, Shibata R, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999). 37: 1160-5. PMID 15319676 DOI: 10.1097/01.qai.0000136091.72955.4b  0.405
2003 Ackers ML, Parekh B, Evans TG, Berman P, Phillips S, Allen M, McDougal JS. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. The Journal of Infectious Diseases. 187: 879-86. PMID 12660933 DOI: 10.1086/368169  0.447
2003 Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, Hirsch A, Ippolito T, Luck A, Longhi M, Gulati V, Winslow N, Gurwith M, Sinangil F, Berman PW. Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials. Aids (London, England). 17: 147-56. PMID 12545073 DOI: 10.1097/01.aids.0000050786.28043.62  0.327
2001 Lee SA, Orque R, Escarpe PA, Peterson ML, Good JW, Zaharias EM, Berman PW, Sheppard HW, Shibata R. Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates. Vaccine. 20: 563-76. PMID 11672923 DOI: 10.1016/S0264-410X(01)00334-6  0.458
1999 Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, Johnson A, Klaussen M, Prashad H, Köhne C, deWit C, Gregory TJ. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology. 265: 1-9. PMID 10603312 DOI: 10.1006/viro.1999.0031  0.398
1999 Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. Aids Research and Human Retroviruses. 15: 921-30. PMID 10408729 DOI: 10.1089/088922299310638  0.497
1999 Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Aids Research and Human Retroviruses. 15: 115-32. PMID 10029244 DOI: 10.1089/088922299311547  0.459
1998 Cleland JL, Lim A, Daugherty A, Barron L, Desjardin N, Duenas ET, Eastman DJ, Vennari JC, Wrin T, Berman P, Murthy KK, Powell MF. Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. Journal of Pharmaceutical Sciences. 87: 1489-95. PMID 10189254 DOI: 10.1021/js980263f  0.364
1998 Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. Aids Research and Human Retroviruses. 14: S325-31. PMID 9814961  0.386
1998 Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. Aids Research and Human Retroviruses. 14: S277-89. PMID 9814956  0.407
1997 Berman PW, Gray AM, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, Francis DP, Gorse G, Schwartz DH. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. The Journal of Infectious Diseases. 176: 384-97. PMID 9237703  0.443
1996 Cleland JL, Barrón L, Berman PW, Daugherty A, Gregory T, Lim A, Vennari J, Wrin T, Powell MF. Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. Journal of Pharmaceutical Sciences. 85: 1346-9. PMID 8961151 DOI: 10.1021/js960047b  0.342
1996 Gorse GJ, Yang EY, Belshe RB, Berman PW. Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group. Clinical and Diagnostic Laboratory Immunology. 3: 769-73. PMID 8914773  0.481
1996 Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, Matthews TJ. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Clinical and Diagnostic Laboratory Immunology. 3: 378-86. PMID 8807200  0.495
1996 Berman PW, Murthy KK, Wrin T, Vennari JC, Cobb EK, Eastman DJ, Champe M, Nakamura GR, Davison D, Powell MF, Bussiere J, Francis DP, Matthews T, Gregory TJ, Obijeski JF. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. The Journal of Infectious Diseases. 173: 52-9. PMID 8537682  0.371
1995 Weissburg RP, Berman PW, Cleland JL, Eastman D, Farina F, Frie S, Lim A, Mordenti J, Nguyen TT, Peterson MR. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharmaceutical Research. 12: 1439-46. PMID 8584477 DOI: 10.1023/A:1016266916893  0.429
1995 Cleland JL, Powell MF, Lim A, Barron L, Berman PW, Nunberg JH, Eastman DJ, Wrin T, Vennari JC, Murthy KK, Kensil CR, Wu JY. Development of a single administration subunit vaccine for HIV-1 Proceedings of the Controlled Release Society. 570-571.  0.384
1994 Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology. 68: 6006-13. PMID 8057475  0.436
1994 Berman PW, Nakamura GR. Adhesion mediated by intercellular adhesion molecule 1 attenuates the potency of antibodies that block HIV-1 gp160-dependent syncytium formation. Aids Research and Human Retroviruses. 10: 585-93. PMID 7917519  0.397
1994 Belshe RB, Gorse GJ, Graham BS, Wright P, Keefer MC, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twaddell T, Berman PW, Gregory T, Izu AE, et al. Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1 Jama: the Journal of the American Medical Association. 272: 475-480. PMID 7913731 DOI: 10.1001/JAMA.272.6.475  0.435
1994 Cleland JL, Powell MF, Lim A, Barrón L, Berman PW, Eastman DJ, Nunberg JH, Wrin T, Vennari JC. Development of a single-shot subunit vaccine for HIV-1. Aids Research and Human Retroviruses. 10: S21-6. PMID 7865303  0.399
1994 Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, Byrn RA. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. Aids (London, England). 8: 591-601. PMID 7520248 DOI: 10.1097/00002030-199405000-00004  0.405
1993 Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. Journal of Virology. 67: 6179-91. PMID 7690420  0.494
1993 Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. Journal of Virology. 67: 6179-6191. DOI: 10.1128/jvi.67.10.6179-6191.1993  0.353
1992 Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. Journal of Virology. 66: 4464-9. PMID 1602554  0.472
1992 McCutchan FE, Hegerich PA, Brennan TP, Phanuphak P, Singharaj P, Jugsudee A, Berman PW, Gray AM, Fowler AK, Burke DS. Genetic variants of HIV-1 in Thailand. Aids Research and Human Retroviruses. 8: 1887-95. PMID 1489577  0.304
1991 Haffar OK, Dowbenko DJ, Berman PW. The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes. Virology. 180: 439-41. PMID 1984664 DOI: 10.1016/0042-6822(91)90054-F  0.332
1990 Lucas C, Peterson ML, Bennett GL, Frie SW, Berman PW, Chen AB. A sensitive radioimmunoprecipitation assay for the detection and quantitation of antibodies to the envelope glycoprotein gp120 of the human immunodeficiency virus (HIV-1). Aids Research and Human Retroviruses. 6: 357-70. PMID 2340201  0.443
1990 Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 345: 622-5. PMID 2190095 DOI: 10.1038/345622a0  0.447
1989 Anderson KP, Lucas C, Hanson CV, Londe HF, Izu A, Gregory T, Ammann A, Berman PW, Eichberg JW. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. The Journal of Infectious Diseases. 160: 960-9. PMID 2555423  0.363
1989 Berman PW, Riddle L, Nakamura G, Haffar OK, Nunes WM, Skehel P, Byrn R, Groopman J, Matthews T, Gregory T. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. Journal of Virology. 63: 3489-98. PMID 2545918 DOI: 10.1128/jvi.63.8.3489-3498.1989  0.311
1988 Torseth JW, Berman PW, Merigan TC. Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. Aids Research and Human Retroviruses. 4: 23-30. PMID 2835070 DOI: 10.1089/Aid.1988.4.23  0.336
1988 Berman PW, Groopman JE, Gregory T, Clapham PR, Weiss RA, Ferriani R, Riddle L, Shimasaki C, Lucas C, Lasky LA. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proceedings of the National Academy of Sciences of the United States of America. 85: 5200-4. PMID 2455898  0.451
1987 Eichberg JW, Zarling JM, Alter HJ, Levy JA, Berman PW, Gregory T, Lasky LA, McClure J, Cobb KE, Moran PA. T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. Journal of Virology. 61: 3804-8. PMID 3500328 DOI: 10.1128/Jvi.61.12.3804-3808.1987  0.372
1987 Eichberg JW, Zarling JM, Alter HJ, Levy JA, Berman PW, Gregory T, Lasky LA, McClure J, Cobb KE, Moran PA. T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. Journal of Virology. 61: 3804-3808. DOI: 10.1128/jvi.61.12.3804-3808.1987  0.37
1987 Berman PW. Synthetic peptides as virus vaccines: Recombinant subunit vaccines Annales De L'Institut Pasteur Virology. 138: 273-278.  0.305
1986 Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, Dowbenko DJ, Nakamura GR, Nunes WM, Renz ME, Berman PW. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (New York, N.Y.). 233: 209-12. PMID 3014647 DOI: 10.1126/science.3014647  0.414
1986 Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 324: 572-5. PMID 2431324 DOI: 10.1038/324572A0  0.434
1986 Cohen GH, Isola VJ, Kuhns J, Berman PW, Eisenberg RJ. Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting. Journal of Virology. 60: 157-66. PMID 2427745 DOI: 10.1128/Jvi.60.1.157-166.1986  0.314
1985 Berman PW, Gregory T, Crase D, Lasky LA. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science (New York, N.Y.). 227: 1490-2. PMID 2983428  0.307
1984 Berman PW, Heinemann SF. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice. Journal of Immunology (Baltimore, Md. : 1950). 132: 711-7. PMID 6690616  0.486
1980 Berman PW, Harbury HA. Immunochemistry of cytochrome c. Identification of antigenic determinants through the study of hybrid molecules. The Journal of Biological Chemistry. 255: 6133-7. PMID 6156157  0.658
1977 Barstow LE, Young RS, Yakali E, Sharp JJ, O'Brien JC, Berman PW, Harbury HA. Semisynthetic cytochrome c. Proceedings of the National Academy of Sciences of the United States of America. 74: 4248-50. PMID 200910 DOI: 10.1073/Pnas.74.10.4248  0.63
Show low-probability matches.